[
    {
        "file_name": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement.pdf",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "1.39 Licensed Product means the finished dosage forms (including final packaging) of the biosimilars containing Ranibizumab which have been Developed and/or are being Developed by Bioeq to each of the Existing Reference Products ([***]). For clarity, Licensed Products include without limitation Vial Products and PFS Products, and shall extend to any New Products to the extent this Agreement is amended in accordance with Section 3.4",
                "changed_text": "1.39 Finished Dosage means the finished dosage forms (including final packaging) of the biosimilars containing Ranibizumab which have been Developed and/or are being Developed by Bioeq to each of the Existing Reference Products ([***]). For clarity, Licensed Products include without limitation Vial Products and PFS Products, and shall extend to any New Products to the extent this Agreement is amended in accordance with Section 3.4",
                "explanation": "The term 'Licensed Product' is a defined term of this contract. By replacing the original term with 'Finished Dosage' in the definition of 1.39, there arises a contradiction when other sections of the contract refer to 'Licensed Product.'",
                "location": "Section 1.39"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "6.  COMMERCIALIZATION\n6.1 General. Subject to the terms and conditions of this Agreement, Licensee shall have the sole right and obligation to conduct the Commercialization of the Licensed Products in the Field in the Territory, including the sole right to conduct the following activities: (a) developing and executing a commercial launch and pre-launch plan; (b) set-up of distribution network in the Territory, negotiation of wholesaler contracts and negotiations with buyer groups (including group purchasing organizations) and key accounts; (c) negotiating with public and private health insurance companies and governmental authorities regarding the price and reimbursement status of the Licensed Products and obtaining and maintaining pricing and reimbursement approvals; (d) marketing,\nmedical affairs, and promotion (including by entertaining a dedicated and sufficiently qualified sales staff, providing for appropriate\nincentive mechanisms for such sales staff, attending relevant conferences, interacting with key opinion leaders, etc.); (e) set-up of hub\nservices including pre-authorization and reimbursement support and co-pay assist programs; (f) booking of sales and performance of\nrelated services; (g) handling all aspects of order processing, invoicing and collection, inventory and receivables; (h) providing\ncustomer support, including handling medical queries, and performing other related functions; and (i) dealing with any Remedial\nActions in relation to the Licensed Products in the Field in the Territory. As between the Parties, Licensee shall be solely responsible\nfor all costs and expenses in connection with the Commercialization of the Licensed Products in the Field in the Territory, unless\notherwise agreed in relation to costs for Remedial Actions in the Territory under Annex 2 and/or the Manufacturing and Supply\nAgreement.",
                "changed_text": "6.  COMMERCIALIZATION\n6.1 General. Subject to the terms and conditions of this Agreement, Licensee shall have the sole right and obligation to conduct the Distribution of the Licensed Products in the Field in the Territory, including the sole right to conduct the following activities: (a) developing and executing a commercial launch and pre-launch plan; (b) set-up of distribution network in the Territory, negotiation of wholesaler contracts and negotiations with buyer groups (including group purchasing organizations) and key accounts; (c) negotiating with public and private health insurance companies and governmental authorities regarding the price and reimbursement status of the Licensed Products and obtaining and maintaining pricing and reimbursement approvals; (d) marketing,\nmedical affairs, and promotion (including by entertaining a dedicated and sufficiently qualified sales staff, providing for appropriate\nincentive mechanisms for such sales staff, attending relevant conferences, interacting with key opinion leaders, etc.); (e) set-up of hub\nservices including pre-authorization and reimbursement support and co-pay assist programs; (f) booking of sales and performance of\nrelated services; (g) handling all aspects of order processing, invoicing and collection, inventory and receivables; (h) providing\ncustomer support, including handling medical queries, and performing other related functions; and (i) dealing with any Remedial\nActions in relation to the Licensed Products in the Field in the Territory. As between the Parties, Licensee shall be solely responsible\nfor all costs and expenses in connection with the Commercialization of the Licensed Products in the Field in the Territory, unless\notherwise agreed in relation to costs for Remedial Actions in the Territory under Annex 2 and/or the Manufacturing and Supply\nAgreement.",
                "explanation": "By changing the term 'Commercialization' in the first line to 'Distribution', this introduces a conflict because the remainder of the text refers to 'Commercialization' and it is unclear whether the initial change is meant to encompass the entire commercialization process or a distinct aspect of it.",
                "location": "Section 6.1"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "4.1 Regulatory Filings. Subject to the terms and conditions of this Agreement, including Sections 3.5 and 4.4 herein, Bioeq shall be solely responsible for all regulatory activities necessary to obtain Regulatory Approval of the Licensed Products in the Field in the Territory, including filing Biologics License Applications for the Licensed Products in the Field in the Territory, and shall bear all costs and expenses relating thereto.",
                "changed_text": "4.1 Regulatory Filings. Subject to the terms and conditions of this Agreement, including Sections 3.5 and 4.4 herein, Bioeq shall be solely responsible for all regulatory actions necessary to obtain Regulatory Approval of the Licensed Products in the Field in the Territory, including filing Biologics License Applications for the Licensed Products in the Field in the Territory, and shall bear all costs and expenses relating thereto.",
                "explanation": "By replacing 'regulatory activities' with 'regulatory actions,' it suggests a narrower scope than what is normally understood as 'activities'. This change is inconsistent as it may create confusion regarding the responsibilities of each party in the section.",
                "location": "Section 4.1"
            }
        ]
    }
]